MAP1LC3A and glioblastoma: It was found that treatment of CD133/PROM1HIGH patient-derived GBM cells with 2-DG significantly enhanced accumulation of p62/SQSTM1 (p < 0.05), MAP1LC3A-II (p < 0.05), an MAP1LC3B-II (p < 0.0001) following treatment with CQ compared to control cells treated with CQ, indicating elevated autophagic flux in 2-DG-treated cells (Fig. 4b).